“NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research”

SOL #: a1889d703b944dd382407ffc06fe195dSpecial Notice

Overview

Buyer

Health And Human Services
National Institutes Of Health
NIH NCI
Bethesda, MD, 20892, United States

Place of Performance

Place of performance not available

NAICS

No NAICS code specified

PSC

No PSC code specified

Set Aside

No set aside specified

Timeline

1
Posted
Jun 1, 2026
2
Action Date
Jun 18, 2026, 8:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

This is a Special Notice from the National Cancer Institute (NCI), publicizing a subcontract opportunity at the Frederick National Laboratory for Cancer Research (FNLCR). Leidos Biomedical Research, Inc. (Leidos Biomed), the operator of FNLCR, is seeking a US-based Contract Development and Manufacturing Organization (CDMO) to provide nanofiltration, fill and finish, and release testing services for a recombinant protein vaccine candidate for a US-based Phase 1 clinical trial. This notice is for informational purposes only and is not a formal solicitation.

Scope of Work

Leidos Biomed, in support of the NIAID DMID NextGen clinical trials, requires a CDMO to manage and conduct activities for customized gap-filling for a vaccine candidate. Specifically, the CDMO will perform nanofiltration processing, fill and finish, and release testing for a recombinant protein vaccine for SARS-CoV-2, generated from the 1c-SApNP® platform (CHO Expression System). The resulting drug product is intended for a US-based Phase 1 clinical trial. All services must comply with current Good Manufacturing Practices (cGMP) and US Pharmacopeia (USP) standards.

Contract & Timeline

  • Type: Special Notice (Subcontract Opportunity)
  • Set-Aside: None specified (for a subcontract opportunity)
  • Response Date (for this notice): June 18, 2026, 4 PM ET
  • Published: June 1, 2026
  • Solicitation/RFP No: S26-125 (for the actual subcontract opportunity)

Additional Notes

This Special Notice is for informational purposes only; no offers are being requested, and the government assumes no liability for any costs incurred in responding. Any submissions provided will become government property. Interested parties should monitor the FNLCR website (https://frederick.cancer.gov/workwithus/solicitations) for additional information on business opportunities. For a copy of the actual Solicitation/RFP No: S26-125, contact Kimberly Iman at kimberly.iman@nih.gov.

People

Points of Contact

Kimberly ImanPRIMARY

Files

Files

Download

Versions

Version 1Viewing
Special Notice
Posted: Jun 1, 2026
“NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research” | GovScope